As an orally administered small tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), KIT and platelet-derived growth factor receptor, sunitinib has been demonstrated active in patients with recurrent malignant meningioma in a phase II trial where the 6-month progression-free survival (PFS) rate in the cohort of anaplastic and atypical meningiomas was 42% and the expression of VEGFR2 in the tumor tissue was associated with favorable PFS (16). This evidence concerns the gene KDR and Atypical Meningioma.